Search Results - "Harding, Thomas C"

Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy by Zboralski, Dirk, Hoehne, Aileen, Bredenbeck, Anne, Schumann, Anne, Nguyen, Minh, Schneider, Eberhard, Ungewiss, Jan, Paschke, Matthias, Haase, Christian, von Hacht, Jan L., Kwan, Tanya, Lin, Kevin K., Lenore, Jan, Harding, Thomas C., Xiao, Jim, Simmons, Andrew D., Mohan, Ajay-Mohan, Beindorff, Nicola, Reineke, Ulrich, Smerling, Christiane, Osterkamp, Frank

“…Purpose Fibroblast activation protein (FAP) is a membrane-bound protease that has limited expression in normal adult tissues but is highly expressed in the…”
Get full text

Aurora kinase A drives the evolution of resistance to third-generation EGFR inhibitors in lung cancer by Shah, Khyati N., Bhatt, Roma, Rotow, Julia, Rohrberg, Julia, Olivas, Victor, Wang, Victoria E., Hemmati, Golzar, Martins, Maria M., Maynard, Ashley, Kuhn, Jonathan, Galeas, Jacqueline, Donnella, Hayley J., Kaushik, Swati, Ku, Angel, Dumont, Sophie, Krings, Gregor, Haringsma, Henry J., Robillard, Liliane, Simmons, Andrew D., Harding, Thomas C., McCormick, Frank, Goga, Andrei, Blakely, Collin M., Bivona, Trever G., Bandyopadhyay, Sourav

“…Although targeted therapies often elicit profound initial patient responses, these effects are transient due to residual disease leading to acquired…”
Get full text

Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients by Chabon, Jacob J., Simmons, Andrew D., Lovejoy, Alexander F., Esfahani, Mohammad S., Newman, Aaron M., Haringsma, Henry J., Kurtz, David M., Stehr, Henning, Scherer, Florian, Karlovich, Chris A., Harding, Thomas C., Durkin, Kathleen A., Otterson, Gregory A., Purcell, W. Thomas, Camidge, D. Ross, Goldman, Jonathan W., Sequist, Lecia V., Piotrowska, Zofia, Wakelee, Heather A., Neal, Joel W., Alizadeh, Ash A., Diehn, Maximilian

“…Circulating tumour DNA (ctDNA) analysis facilitates studies of tumour heterogeneity. Here we employ CAPP-Seq ctDNA analysis to study resistance mechanisms in…”
Get full text

BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma by Lin, Kevin K, Harrell, Maria I, Oza, Amit M, Oaknin, Ana, Ray-Coquard, Isabelle, Tinker, Anna V, Helman, Elena, Radke, Marc R, Say, Carmen, Vo, Lan-Thanh, Mann, Elaina, Isaacson, Jeffrey D, Maloney, Lara, O'Malley, David M, Chambers, Setsuko K, Kaufmann, Scott H, Scott, Clare L, Konecny, Gottfried E, Coleman, Robert L, Sun, James X, Giordano, Heidi, Brenton, James D, Harding, Thomas C, McNeish, Iain A, Swisher, Elizabeth M

“…A key resistance mechanism to platinum-based chemotherapies and PARP inhibitors in -mutant cancers is the acquisition of reversion mutations that restore…”
Get more information

Evaluation of in vitro absorption, distribution, metabolism, and excretion and assessment of drug-drug interaction of rucaparib, an orally potent poly(ADP-ribose) polymerase inhibitor by Liao, Mingxiang, Jaw-Tsai, Sarah, Beltman, Jeri, Simmons, Andrew D., Harding, Thomas C., Xiao, Jim J.

“…1. The absorption, distribution, metabolism, elimination, and drug-drug interaction (DDI) potential of the poly(ADP-ribose) polymerase (PARP) inhibitor…”
Get full text

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial by van den Eertwegh, Alfons JM, MD, Versluis, Jurjen, MD, van den Berg, H Pieter, MD, Santegoets, Saskia JAM, PhD, van Moorselaar, R Jeroen A, Prof, van der Sluis, Tim M, MD, Gall, Helen E, MNAP, Harding, Thomas C, MD, Jooss, Karin, PhD, Lowy, Israel, MD, Pinedo, Herbert M, Prof, Scheper, Rik J, Prof, Stam, Anita GM, BSc, von Blomberg, B Mary E, PhD, de Gruijl, Tanja D, PhD, Hege, Kristen, MD, Sacks, Natalie, MD, Gerritsen, Winald R, Prof

“…Summary Background The granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells vaccine (GVAX) has antitumour activity…”
Get full text

Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor by Helman, Elena, Nguyen, Minh, Karlovich, Chris A., Despain, Darrin, Choquette, A. Karin, Spira, Alexander I., Yu, Helena A., Camidge, D. Ross, Harding, Thomas C., Lanman, Richard B., Simmons, Andrew D.

“…The genomic alterations driving resistance to third-generation EGFR tyrosine kinase inhibitors (TKIs) are not well established, and collecting tissue biopsy…”
Get full text

A Quantitative Chemotherapy Genetic Interaction Map Reveals Factors Associated with PARP Inhibitor Resistance by Hu, Hsien-Ming, Zhao, Xin, Kaushik, Swati, Robillard, Lilliane, Barthelet, Antoine, Lin, Kevin K., Shah, Khyati N., Simmons, Andy D., Raponi, Mitch, Harding, Thomas C., Bandyopadhyay, Sourav

“…Chemotherapy is used to treat most cancer patients, yet our understanding of factors that dictate response and resistance to such drugs remains limited. We…”
Get full text

Stable antibody expression at therapeutic levels using the 2A peptide by Fang, Jianmin, Qian, Jing-Jing, Yi, Saili, Harding, Thomas C, Tu, Guang Huan, VanRoey, Melinda, Jooss, Karin

“…Therapeutic monoclonal antibodies (mAbs) are currently being developed for the treatment of cancer and other diseases. Despite clinical success, widespread…”
Get full text

Vascular Endothelial Growth Factor Blockade Reduces Intratumoral Regulatory T Cells and Enhances the Efficacy of a GM-CSF–Secreting Cancer Immunotherapy by LI, Betty, LALANI, Alshad S, HARDING, Thomas C, LUAN, Bo, KOPRIVNIKAR, Kathryn, HUANTU, Guang, PRELL, Rodney, VAN ROEY, Melinda J, SIMMONS, Andrew D, JOOSS, Karin

“…Purpose: The purpose of the present study was to evaluate granulocyte macrophage colony-stimulating factor (GM-CSF)–secreting tumor cell immunotherapy in…”
Get full text

Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor by JIANMIN LIN, LALANI, Alshad S, MITALO, Kari, JOOSS, Karin, HARDING, Thomas C, GONZALEZ, Melissa, WU, Wei-Wei, BO LUAN, GUANG HUAN TU, KOPRIVNIKAR, Kathryn, VANROEY, Melinda J, YULONG HE

“…The presence of metastases in regional lymph nodes is a strong indicator of poor patient survival in many types of cancer. It has recently been shown that the…”
Get full text

K562/GM-CSF Immunotherapy Reduces Tumor Burden in Chronic Myeloid Leukemia Patients with Residual Disease on Imatinib Mesylate by Smith, B Douglas, Kasamon, Yvette L, Kowalski, Jeanne, Gocke, Christopher, Murphy, Kathleen, Miller, Carole B, Garrett-Mayer, Elizabeth, Tsai, Hua-Ling, Qin, Lu, Chia, Christina, Biedrzycki, Barbara, Harding, Thomas C, Tu, Guang Haun, Jones, Richard, Hege, Kristen, Levitsky, Hyam I

“…Purpose: Chronic myeloid leukemia (CML) can be responsive to T-cell–mediated immunity. K562/granulocyte macrophage-colony stimulating factor (GM-CSF) is a…”
Get full text

BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer by Lui, Goldie Y.L., Shaw, Reid, Schaub, Franz X., Stork, Isabella N., Gurley, Kay E., Bridgwater, Caroline, Diaz, Robert L., Rosati, Rachele, Swan, Hallie A., Ince, Tan A., Harding, Thomas C., Gadi, Vijayakrishna K., Goff, Barbara A., Kemp, Christopher J., Swisher, Elizabeth M., Grandori, Carla

“…Homologous recombination deficiencies (HRD) are present in approximately half of epithelial ovarian cancers, for which PARP inhibitors (PARPi) are becoming a…”
Get full text

Virus-Mediated Transduction of Murine Retina with Adeno-Associated Virus: Effects of Viral Capsid and Genome Size by Yang, Grace S, Schmidt, Michael, Yan, Ziying, Lindbloom, Jonathan D, Harding, Thomas C, Donahue, Brian A, Engelhardt, John F, Kotin, Robert, Davidson, Beverly L

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial by Swisher, Elizabeth M, Dr Prof, Lin, Kevin K, PhD, Oza, Amit M, Prof, Scott, Clare L, PhD, Giordano, Heidi, MA, Sun, James, PhD, Konecny, Gottfried E, MD, Coleman, Robert L, Prof, Tinker, Anna V, MD, O'Malley, David M, MD, Kristeleit, Rebecca S, MD, Ma, Ling, MD, Bell-McGuinn, Katherine M, MD, Brenton, James D, Prof, Cragun, Janiel M, MD, Oaknin, Ana, MD, Ray-Coquard, Isabelle, Prof, Harrell, Maria I, PhD, Mann, Elaina, MS, Kaufmann, Scott H, Prof, Floquet, Anne, MD, Leary, Alexandra, MD, Harding, Thomas C, PhD, Goble, Sandra, MS, Maloney, Lara, BA, Isaacson, Jeff, PhD, Allen, Andrew R, MD, Rolfe, Lindsey, MBChB, Yelensky, Roman, PhD, Raponi, Mitch, PhD, McNeish, Iain A, Prof

“…Summary Background Poly(ADP-ribose) polymerase (PARP) inhibitors have activity in ovarian carcinomas with homologous recombination deficiency. Along with BRCA1…”
Get full text

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma by Kondrashova, Olga, Nguyen, Minh, Shield-Artin, Kristy, Tinker, Anna V, Teng, Nelson N H, Harrell, Maria I, Kuiper, Michael J, Ho, Gwo-Yaw, Barker, Holly, Jasin, Maria, Prakash, Rohit, Kass, Elizabeth M, Sullivan, Meghan R, Brunette, Gregory J, Bernstein, Kara A, Coleman, Robert L, Floquet, Anne, Friedlander, Michael, Kichenadasse, Ganessan, O'Malley, David M, Oza, Amit, Sun, James, Robillard, Liliane, Maloney, Lara, Bowtell, David, Giordano, Heidi, Wakefield, Matthew J, Kaufmann, Scott H, Simmons, Andrew D, Harding, Thomas C, Raponi, Mitch, McNeish, Iain A, Swisher, Elizabeth M, Lin, Kevin K, Scott, Clare L

“…High-grade epithelial ovarian carcinomas containing mutated or ( ) homologous recombination (HR) genes are sensitive to platinum-based chemotherapy and PARP…”
Get more information

Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC by Walter, Annette O, Sjin, Robert Tjin Tham, Haringsma, Henry J, Ohashi, Kadoaki, Sun, Jing, Lee, Kwangho, Dubrovskiy, Aleksandr, Labenski, Matthew, Zhu, Zhendong, Wang, Zhigang, Sheets, Michael, St Martin, Thia, Karp, Russell, van Kalken, Dan, Chaturvedi, Prasoon, Niu, Deqiang, Nacht, Mariana, Petter, Russell C, Westlin, William, Lin, Kevin, Jaw-Tsai, Sarah, Raponi, Mitch, Van Dyke, Terry, Etter, Jeff, Weaver, Zoe, Pao, William, Singh, Juswinder, Simmons, Andrew D, Harding, Thomas C, Allen, Andrew

“…Patients with non-small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine…”
Get more information

Clinical Pharmacokinetics and Pharmacodynamics of Rucaparib by Liao, Mingxiang, Beltman, Jeri, Giordano, Heidi, Harding, Thomas C., Maloney, Lara, Simmons, Andrew D., Xiao, Jim J.

“…Rucaparib is an oral small-molecule poly(ADP-ribose) polymerase inhibitor indicated for patients with recurrent ovarian cancer in the maintenance and treatment…”
Get full text

Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition by Zboralski, Dirk, Osterkamp, Frank, Christensen, Esben, Bredenbeck, Anne, Schumann, Anne, Hoehne, Aileen, Schneider, Eberhard, Paschke, Matthias, Ungewiss, Jan, Haase, Christian, Robillard, Liliane, Simmons, Andrew D., Harding, Thomas C., Nguyen, Minh

“…Purpose FAP is a membrane-bound protease under investigation as a pan-cancer target, given its high levels in tumors but limited expression in normal tissues…”
Get full text

The Multi-Kinase Inhibitor Lucitanib Enhances the Antitumor Activity of Coinhibitory and Costimulatory Immune Pathway Modulators in Syngeneic Models by Robillard, Liliane, Liao, Mingxiang, Nguyen, Minh, Harding, Thomas C., Simmons, Andrew D., Dusek, Rachel L.

“…Lucitanib is a multi-tyrosine kinase inhibitor whose targets are associated with angiogenesis and other key cancer and immune pathways. Its antiangiogenic…”
Get full text